Information Provided By:
Fly News Breaks for April 25, 2019
ALKS
Apr 25, 2019 | 15:20 EDT
Piper Jaffray analyst Danielle C. Brill said she thinks it will be difficult for Alkermes to meet FY19 guidance given current IQVIA prescription trends and the fact that Aristada sales missed Q1 guidance by about $10M. The analyst, who expects revenues to continue to plateau, keeps a Neutral rating on Alkermes shares and cut her price target on the stock to $30 from $32 following the company's Q1 report.
News For ALKS From the Last 2 Days
There are no results for your query ALKS